Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?

Cancer statistics, 2019

(2019) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison

(2019) Michael B Atkins et al.   Immunotherapy

First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis

(2019) Bastian Schilling et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

(2019) O Hamid et al.   ANNALS OF ONCOLOGY

Efficacy of PD-1–based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma

(2019) Sophia Kreft et al.   EUROPEAN JOURNAL OF CANCER

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

(2019) Caroline Robert et al.   LANCET ONCOLOGY

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

(2019) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM

(2019) Karl D. Lewis et al.   BRITISH JOURNAL OF CANCER

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2019) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical outcomes of BRAF plus MEK inhibition in melanoma: A meta‐analysis and systematic review

(2019) Qingliang Yu et al.   Cancer Medicine

Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations

(2019) Christian Menzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Combined ipilimumab and nivolumab first‐line and after BRAF‐targeted therapy in advanced melanoma

(2019) Robert Mason et al.   Pigment Cell & Melanoma Research

Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice

(2019) Anna M. Czarnecka et al.   Targeted Oncology

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab

(2019) Justin C. Moser et al.   Cancer Medicine

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

(2019) David Liu et al.   NATURE MEDICINE

Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade

(2018) Sachet A. Shukla et al.   CELL

Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial

(2018) James Larkin et al.   JOURNAL OF CLINICAL ONCOLOGY

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma

(2018) Caroline Robert et al.   JOURNAL OF CLINICAL ONCOLOGY

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

(2018) Reinhard Dummer et al.   LANCET ONCOLOGY

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study

(2018) Georgina V Long et al.   LANCET ONCOLOGY

Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial

(2018) Matteo S. Carlino et al.   EUROPEAN JOURNAL OF CANCER

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

(2018) Reinhard Dummer et al.   LANCET ONCOLOGY

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

(2018) Hussein A. Tawbi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600–Mutated Metastatic Melanoma

(2018) Axel Hauschild et al.   JAMA Oncology

Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy

(2018) Karim R. Saab et al.   CANCER

Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III Melanoma

(2018) Axel Hauschild et al.   JOURNAL OF CLINICAL ONCOLOGY

Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy

(2018) Paolo A. Ascierto et al.   JAMA Oncology

MAPK pathway in melanoma part II—secondary and adaptive resistance mechanisms to BRAF inhibition

(2017) Teresa Amaral et al.   EUROPEAN JOURNAL OF CANCER

The mitogen-activated protein kinase pathway in melanoma part I – Activation and primary resistance mechanisms to BRAF inhibition

(2017) Teresa Amaral et al.   EUROPEAN JOURNAL OF CANCER

Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma

(2017) Lisa Zimmer et al.   EUROPEAN JOURNAL OF CANCER

Dabrafenib plus trametinib in patients with BRAF V600 -mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

(2017) Michael A Davies et al.   LANCET ONCOLOGY

Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance

(2017) Sydney M. Shaffer et al.   NATURE

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Quality-of-life outcomes in patients with advanced melanoma: A review of the literature

(2017) Karen A. Malkhasyan et al.   Pigment Cell & Melanoma Research

Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions

(2017) Antje Sucker et al.   Nature Communications

Resistance to checkpoint blockade therapy through inactivation of antigen presentation

(2017) Moshe Sade-Feldman et al.   Nature Communications

Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series

(2016) Matteo S Carlino et al.   BRITISH JOURNAL OF CANCER

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

(2016) Willy Hugo et al.   CELL

Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

(2016) Paolo A Ascierto et al.   LANCET ONCOLOGY

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

(2016) Daniel Sanghoon Shin et al.   Cancer Discovery

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

(2015) Willy Hugo et al.   CELL

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

(2015) Georgina V Long et al.   LANCET

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

(2014) Allison Ackerman et al.   CANCER

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

(2014) Georgina V. Long et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

(2014) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Synergistic Combination of Novel Tubulin Inhibitor ABI-274 and Vemurafenib Overcomes Vemurafenib Acquired Resistance in BRAFV600E Melanoma

(2013) J. Wang et al.   MOLECULAR CANCER THERAPEUTICS

Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors

(2013) Jaehyuk Choi et al.   Pigment Cell & Melanoma Research

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

(2013) H. Shi et al.   Cancer Discovery

A Landscape of Driver Mutations in Melanoma

(2012) Eran Hodis et al.   CELL

Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma

(2012) Vipin Yadav et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression

(2011) K. H. T. Paraiso et al.   CANCER RESEARCH

Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases

(2011) Paul W. Sperduto et al.   JOURNAL OF CLINICAL ONCOLOGY

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

(2011) Poulikos I. Poulikakos et al.   NATURE

Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway

(2011) Mohammad Atefi et al.   PLoS One

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Staging and Prognosis of Cutaneous Melanoma

(2010) Paxton V. Dickson et al.   Surgical Oncology Clinics of North America